• On Day 1, investigator confirmed that "Clinical" SLEDAI-2K numerical score was ≥ the "Clinical" SLEDAI-2K numerical score completed at the initiation of screening period
• On Day 1, the investigator or designee contacted the IVRS/IWRS and provided the patient identification number and patient's baseline characteristic(s), including the confirmatory "Clinical" SLEDAI-2K numerical score, to verify patient identity
• The IVRS/IWRS assigned a treatment arm and investigational product kit number(s) to the patient • Confirmation of this information was sent to the investigator/designee, who dispensed the investigational product to the patient as per the communication, and recorded the appropriate information in the patient's medical records and investigational product accountability log.
Assessed for eligibility 834
Randomised 432 a. The entry criteria violation and non-receipt of therapy were reported for the same patient. Treatment was administered on Days 1, 15, and 29, and then every 28 days thereafter.
Figure S1
Patient Disposition.
Figure S2
Patients with improvements in SLEDAI-2K organ systems at Week 52.
Treatment was administered on Days 1, 15, and 29, and then every 28 days thereafter. SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index 2000.
Figure S3
Change from baseline in C3 (A) and C4 (B) complement for patients with abnormal levels at baseline.
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Figure S4
Change from baseline in anti-dsDNA by multiplexed assay for patients with abnormal levels (≥100 IU/ml) at baseline. dsDNA, double-stranded DNA.
Figure S5
SRI (4) 
